| Patents for A61P 43 - Drugs for specific purposes, not provided for in groups (156,317) |
|---|
| 01/02/2003 | US20030003169 Prepared by fermenting an aqueous Glycine max (L.) extract with at least one lactic acid bacteria together with at least one yeast |
| 01/02/2003 | US20030003145 Comprises micronized N-piperidino-5-(4-chlorophenyl)-1-(2,4-dichlorophenyl)-4-methylpyrazole-3 -carboxamide |
| 01/02/2003 | US20030003141 Contacting a blood vessel wall cell with an A beta 40 inhibitor, such that cerebral amyloid angiopathy is inhibited |
| 01/02/2003 | US20030003139 Transdermal system that contains a new highly potent gestagen |
| 01/02/2003 | US20030003092 Administering an immunotherapeautic agent in conjunction with a tumour growth restricting agent, in amounts effective to eradicate any advanced or large tumours present |
| 01/02/2003 | US20030003082 Use of poly-Glu,Tyr and T cells treated therewith for neuroprotective therapy |
| 01/02/2003 | US20030003077 A genetic engineered adenoviral vector contains an adenoviral genome from which the open reading frames E1 and/or E3 were deleted and a therapeutic gene or a DNA sequence that encodes for therapeutic proteins useful in fibrosis treatment |
| 01/02/2003 | US20030003071 N-methyltaurine as an active ingredient; giving hair fitness and body, and giving hair a feeling of volume |
| 01/02/2003 | US20030000518 Delivery of nonsteroidal antiinflammatory drugs through an inhalation route |
| 01/02/2003 | EP1270724A2 Guanosine triphosphate-binding protein coupled receptors |
| 01/02/2003 | EP1270584A1 Glucopyranosyloxy benzylbenzene derivatives, medicinal compositions containing the same and intermediates for the preparation of the derivatives |
| 01/02/2003 | EP1270577A1 Furoisoquinoline derivatives, process for producing the same and use thereof |
| 01/02/2003 | EP1270572A1 Condensed pyrazole derivatives, process for producing the same and use thereof |
| 01/02/2003 | EP1270569A1 Substituted tryptophan derivatives |
| 01/02/2003 | EP1270567A1 Pyrazoline derivatives or tetrahydropyridazine derivatives and medicinal use thereof |
| 01/02/2003 | EP1270559A1 Novel imidazole derivatives with anti-inflammatory activity |
| 01/02/2003 | EP1270558A1 "Compound for the treatment of atherosclerotic-thrombotic pathological conditions" |
| 01/02/2003 | EP1270547A1 Novel phenylalanine derivative |
| 01/02/2003 | EP1270003A1 Use of amino acids such as arginine or citrulline for improving the hatchability of eggs |
| 01/02/2003 | EP1270000A2 Benzoic acid substituted benzopyrans for the treatment of atherosclerosis |
| 01/02/2003 | EP1269989A1 Cosmetic or dermatological composition comprising acylaminoamide derivatives |
| 01/02/2003 | EP1269984A1 Cosmetic and/or dermatological andor pharmaceutical composition for topical application containing at least one compound inhibiting 3-beta-HSD enzyme |
| 01/02/2003 | EP1269860A1 Pharmaceutical composition |
| 01/02/2003 | EP1269198A2 Identification of mast/basophil activation inhibitors |
| 01/02/2003 | EP1269196A1 Method of screening for inhibitors of osteopontin |
| 01/02/2003 | EP1269183A1 Assay for agents that induce chemokinesis |
| 01/02/2003 | EP1268835A1 Retinoic acid receptor beta-2, its antagonists, and gene therapy vectors for the treatment of neurological disorders |
| 01/02/2003 | EP1268833A2 Modified nodavirus rna for gene delivery |
| 01/02/2003 | EP1268817A1 Human pyruvate dehydrogenese phosphatase |
| 01/02/2003 | EP1268812A2 Vectors for gene therapy |
| 01/02/2003 | EP1268802A2 Beta-like glycoprotein hormone polypeptide and heterodimer |
| 01/02/2003 | EP1268798A2 Anti-angiogenic and anti-tumor properties of vascostatin and other nidogen domains |
| 01/02/2003 | EP1268792A2 Wnt-7b-like polypeptides and nucleic acids encoding same |
| 01/02/2003 | EP1268786A2 Use of p-selectin glycoprotein ligand-1 (psgl-1) and fragments thereof for the inhibition of thrombosis |
| 01/02/2003 | EP1268783A2 Anti-angiogenic and anti-tumor properties of matin and other laminin domains |
| 01/02/2003 | EP1268781A2 G12l, a gene associated with the thermal response |
| 01/02/2003 | EP1268775A1 The high bone mass gene of 11q13.3 |
| 01/02/2003 | EP1268774A2 Identification of essential genes in prokaryotes |
| 01/02/2003 | EP1268768A2 Targeted chromosomal genomic alterations with modified single stranded oligonucleotides |
| 01/02/2003 | EP1268760A1 Recombinant proteins containing shiga-like toxin and vascular endothelial growth factor fragments |
| 01/02/2003 | EP1268753A2 Human protein tyrosine phosphatase, encoding dna and uses thereof |
| 01/02/2003 | EP1268554A2 Diagnostic and medicament for analysing the cell surface proteome of tumour and inflammatory cells and for treating tumorous and inflammatory diseases, preferably using a specific chemokine receptor analysis and the chemokine receptor-ligand interaction |
| 01/02/2003 | EP1268549A2 Method of identifying inhibitors of tie-2 |
| 01/02/2003 | EP1268540A2 Proteins amf-1 to amf-10 and nucleic acids encoding same |
| 01/02/2003 | EP1268525A2 Macrocyclic ns3-serine protease inhibitors of hepatitis c virus comprising n-cyclic p2 moieties |
| 01/02/2003 | EP1268510A2 Method and materials relating to insulin-like growth factor binding protein-like polypeptides and polynucleotides |
| 01/02/2003 | EP1268504A1 Nucleoside compounds and uses thereof |
| 01/02/2003 | EP1268498A1 Cardioprotective phosphonates and malonates |
| 01/02/2003 | EP1268495A1 Sulfur substituted aryldifluoromethylphosphonic acids as ptp-1b inhibitors |
| 01/02/2003 | EP1268494A1 Sulfur substituted aryldifluoromethylphosphonic acids as ptp-1b inhibitors |
| 01/02/2003 | EP1268493A1 Phosphoramidate prodrugs |
| 01/02/2003 | EP1268489A1 Dihydroimidazo[2,1-b]thiazole and dihydro-5h-thiazolo[3,2-a]pyrimidines as antidepressant agents |
| 01/02/2003 | EP1268487A1 Tricyclic protein kinase inhibitors |
| 01/02/2003 | EP1268484A1 Condensed imidazoles as histamine h3 receptor ligands |
| 01/02/2003 | EP1268483A1 Condensed imidazoles as histamine h3 receptor ligands |
| 01/02/2003 | EP1268479A1 Phenyl-substituted indolizine derivatives and their use as histamine h3 ligands |
| 01/02/2003 | EP1268476A1 5-alkylpyrido[2,3-d]pyrimidines tyrosine kinase inhibitors |
| 01/02/2003 | EP1268472A1 3-aminopyrazole inhibitors of cyclin dependent kinases |
| 01/02/2003 | EP1268469A1 N-(heterocyclyl)benzene or pyridine sulphonamides as antithrombotic agents and anticoagulants |
| 01/02/2003 | EP1268463A2 Polycyclic aryl and heteroaryl substituted 4-pyrones useful for selective inhibition of the coagulation cascade |
| 01/02/2003 | EP1268455A2 Piperazine derivatives |
| 01/02/2003 | EP1268454A1 Succinoylamino heterocycles as inhibitors of a-beta protein production |
| 01/02/2003 | EP1268453A1 Estrogen agonist/antagonist metabolites |
| 01/02/2003 | EP1268448A1 Bicyclic amine derivatives as inhibitors of class 1 receptor tyrosine kinases |
| 01/02/2003 | EP1268445A1 4-amino-5-cyano-2-anilino-pyrimidine derivatives and their use as inhibitors of cell-cycle kinases |
| 01/02/2003 | EP1268444A1 2,4-di(hetero-)arylamino(-oxy)-5-substituted pyrmidines as antineoplastic agents |
| 01/02/2003 | EP1268442A2 Crystalline pharmaceutical |
| 01/02/2003 | EP1268441A1 An intermediate and process for its synthesis |
| 01/02/2003 | EP1268439A1 5-hydroxy indazole derivatives for treating glaucoma |
| 01/02/2003 | EP1268437A1 Inhibitors of protein kinases |
| 01/02/2003 | EP1268435A1 4,5-dihydro-1h-pyrazole derivatives having cb 1-antagonistic activity |
| 01/02/2003 | EP1268434A1 Cyclic lactams as inhibitors of a-beta protein production |
| 01/02/2003 | EP1268433A1 Cyclic lactams as inhibitors of a-beta-protein production |
| 01/02/2003 | EP1268431A1 3-cyanoquinolines,3-cyano-1,6-naphthyridines, and 3-cyano-1,7-naphthyridines as protein kinase inhibitors |
| 01/02/2003 | EP1268429A1 Vitronectin receptor antagonist bicyclic compounds, preparation method and compositions containing same |
| 01/02/2003 | EP1268428A2 Polycyclic aryl and heteroaryl substituted 4-pyridones useful for selective inhibition of the coagulation cascade |
| 01/02/2003 | EP1268427A1 Aminopyridines and their use as anticonvulsants and sodium channel blockers |
| 01/02/2003 | EP1268425A2 Carbamate caspase inhibitors and uses thereof |
| 01/02/2003 | EP1268423A1 Indole derivatives as mcp-1 receptor antagonists |
| 01/02/2003 | EP1268420A1 Chemokine receptor antagonists |
| 01/02/2003 | EP1268419A1 Pyrrolidine derivatives useful as bax inhibitors |
| 01/02/2003 | EP1268413A2 Substituted biphenyl derivatives |
| 01/02/2003 | EP1268412A1 Sulphonamido-substituted bridged bicycloalkyl derivatives |
| 01/02/2003 | EP1268407A1 Propenecarboxylic acid amidoxime derivatives, a process for the preparation thereof, and pharmaceutical compositions containing the same |
| 01/02/2003 | EP1268396A1 Diphenyl ether compounds useful in therapy |
| 01/02/2003 | EP1268389A2 Halogenated triphenylethylene derivatives as selective estrogen receptor modulators |
| 01/02/2003 | EP1268000A1 Spiropiperidine derivatives as melanocortin receptor agonists |
| 01/02/2003 | EP1267945A2 Compositions containing genetically modified lung cancer cells expressing a tgf-beta inhibitor |
| 01/02/2003 | EP1267944A1 Systemic gene delivery vehicles for the treatment of tumors |
| 01/02/2003 | EP1267943A2 Medicament for the stimulation of leucopoiesis and treatment of tumour and protozoan diseases acarinosis and arthropod-borne diseases and a method for production thereof |
| 01/02/2003 | EP1267931A1 Rhodamine derivatives for photodynamic diagnosis and treatment |
| 01/02/2003 | EP1267925A1 Treatment of fungal infection with polyene or beta glucan synthase inhibitor antifungals combined with anti hsp90 antibodies |
| 01/02/2003 | EP1267918A1 Method of treatment using ligand-immunogen conjugates |
| 01/02/2003 | EP1267913A2 Methods for administration of therapeutic agents on an antiangiogenic schedule |
| 01/02/2003 | EP1267908A1 Vaccine for the treatment of atherosclerosis |
| 01/02/2003 | EP1267906A1 Lactams as inhibitors of a-beta protein production |
| 01/02/2003 | EP1267905A2 Composition for the treatment of heart failure |
| 01/02/2003 | EP1267902A1 Cosmetic use of hop and ornithine |
| 01/02/2003 | EP1267901A1 Compositions suitable for the treatment of damage caused by ischemia/reperfusion or oxidative stress |
| 01/02/2003 | EP1267898A2 Bile acid containing prodrugs with enhanced bioavailability |